Zachary Canonico Portfolio
Invests via DIADEMA PARTNERS LP | Managed by Timothy Bassett, Zachary Canonico
Invests via DIADEMA PARTNERS LP
Managed by Timothy Bassett, Zachary Canonico
Automatically Tracked
Zachary Canonico Profile
Operator-turned-angel investor focused on SaaS, fintech and developer tools with hands-on experience scaling product and go-to-market. Zachary Canonico brings founder and engineering experience to early-stage deal sourcing, active board advising, and seed follow-ons; he evaluates capital-efficient business models, unit economics and customer-led distribution. Prior roles span startup founding, product leadership and angel investments across North America, supporting rounds from pre-seed to Series A. Known for operational diligence, founder mentoring and technical due diligence, he networks with venture funds and accelerators to syndicate deals and co-invest. Typical check sizes and sector bias align with high-growth software and platform plays aiming for rapid revenue expansion.
Operator-turned-angel investor focused on SaaS, fintech and developer tools with hands-on experience scaling product and go-to-market. Zachary Canonico brings founder and engineering experience to early-stage deal sourcing, active board advising, and seed follow-ons; he evaluates capital-efficient business models, unit economics and customer-led distribution. Prior roles span startup founding, product leadership and angel investments across North America, supporting rounds from pre-seed to Series A. Known for operational diligence, founder mentoring and technical due diligence, he networks with venture funds and accelerators to syndicate deals and co-invest. Typical check sizes and sector bias align with high-growth software and platform plays aiming for rapid revenue expansion.
Investment Philosophy & Strategy
Operator-led angel investing with a bias toward capital-efficient SaaS, fintech and developer tools; prioritizes businesses with strong unit economics, product-led customer acquisition and clear paths to recurring revenue. Deploys seed to Series A checks with conviction follow-on reserve, favoring hands-on partnerships where technical and GTM scaling add measurable value. Underwrites opportunities by triangulating engineering rigor, founder velocity and early revenue traction, leaning toward rapid revenue expansion but disciplined on churn and CAC payback. Syndicates with funds and accelerators to diversify risk and accelerate portfolio company market access.
Operator-led angel investing with a bias toward capital-efficient SaaS, fintech and developer tools; prioritizes businesses with strong unit economics, product-led customer acquisition and clear paths to recurring revenue. Deploys seed to Series A checks with conviction follow-on reserve, favoring hands-on partnerships where technical and GTM scaling add measurable value. Underwrites opportunities by triangulating engineering rigor, founder velocity and early revenue traction, leaning toward rapid revenue expansion but disciplined on churn and CAC payback. Syndicates with funds and accelerators to diversify risk and accelerate portfolio company market access.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
45.16%
Gain +1.5%
Monthly
2.01%
Yearly
27.11%
Drawdown
18.67%
$268.03M
Equity
Holdings
$268.03M
Investment
$224.72M
$64.18M
Profit +$3.6M
Realized
$20.87M
Unrealized
$43.31M
Dividends
$803,812.14
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
1.5%
Profit
$3.6M
Win %
65%
This Week
Compared To Last Week
Gain
-3.4%
Profit
-$9.44M
Win %
65%
This Month
Compared to last month
Gain
-2.8%
Profit
-$7.71M
Win %
65%
This Year
Compared to last year
Gain
10.63%
Profit
$25.75M
Win %
68%
STTK Shattuck Labs Inc.
+9.24%
+$185,008.32 
PGEN Precigen Inc.
+8.91%
+$24,986.91 
ACRX AcelRx Pharmaceuticals Inc
+7.5%
+$9,213.78 
KOD Kodiak Sciences Inc.
+5.63%
+$443,812.6 
CLYM Climb Biotherapeutics, Inc.
+5.47%
+$191,303.84 
PRQR ProQR Therapeutics N.V.
+5.11%
+$16,207.47 
EPRX Eupraxia Pharmaceuticals Inc.
+4.97%
+$12,400 
TRVI Trevi Therapeutics Inc.
+4.83%
+$17,547.03 
CUE Cue Biopharma, Inc.
+4.72%
+$6,368.76 
EQ Equillium, Inc.
+4.45%
+$47,722.84 
RCUS Arcus Biosciences Inc.
+4.08%
+$273,863.3 
ELVN Enliven Therapeutics, Inc.
+3.99%
+$504.7 
VKTX Viking Therapeutics Inc.
+3.93%
+$751,008.83 
URGN Urogen Pharma Ltd.
+3.53%
+$33,593.27 
RLMD Relmada Therapeutics Inc.
+3.5%
+$35,147.35 
HRMY Harmony Biosciences Holdings, Inc.
+3.43%
+$106,710.02 
MNPR Monopar Therapeutics Inc.
+3.39%
+$5,851.7 
RNA Avidity Biosciences Inc.
+3.32%
+$979.68 
PCVX Vaxcyte, Inc.
+3.19%
+$44,375.67 
REPL Replimune Group Inc.
+3.14%
+$33,217.8 
EYPT EyePoint Pharmaceuticals Inc.
+3.12%
+$70,525.27 
COGT Cogent Biosciences, Inc.
+3.04%
+$376,020.06 
GHRS GH Research plc
+2.98%
+$22,005.52 
CORT Corcept Therapeutics Incorporated
+2.8%
+$25,659 
LPCN Lipocine Inc.
+2.79%
+$3,000 
DNTH Dianthus Therapeutics Inc.
+2.78%
+$28,100 
MNKD MannKind Corporation
+2.76%
+$20,526.33 
INDV Indivior Pharmaceuticals, Inc.
+2.73%
+$76,372.32 
JAZZ Jazz Pharmaceuticals plc
+2.72%
+$362,478.1 
ENTA Enanta Pharmaceuticals Inc.
+2.66%
+$22,733.2 
CELC Celcuity Inc.
+2.6%
+$12,169.06 
CRVS Corvus Pharmaceuticals Inc.
+2.59%
+$89,356.01 
MLYS Mineralys Therapeutics, Inc.
+2.55%
+$17,915.96 
SEPN Septarna Inc.
+2.52%
+$163.62 
CMPS Compass Pathways plc Depositary Receipt
+2.45%
+$9,103.17 
GPCR Structure Therapeutics Inc.
+2.43%
+$82,505.67 
MAZE Maze Therapeutics Inc.
+2.4%
+$10,200 
PHVS Pharvaris N.V.
+2.27%
+$22,283.96 
XERS Xeris Biopharma Holdings, Inc.
+2.21%
+$25,221.74 
MGNX Macrogenics Inc.
+2.2%
+$57,000 
SPRB Spruce Biosciences Inc.
+2.13%
+$9,500 
PRTC PureTech Health plc - ADR
+2.12%
+$2,852.64 
PEPG PepGen Inc.
+2.04%
+$6,791.62 
INCY Incyte Corporation
+1.99%
+$179,217.01 
VYGR Voyager Therapeutics Inc.
+1.9%
+$24,571.24 
IVA Inventiva S.A.
+1.81%
+$28,191.92 
GLUE Monte Rosa Therapeutics, Inc.
+1.58%
+$69,303.59 
RVMD Revolution Medicines Inc.
+1.53%
+$223,206.72 
BBIO BridgeBio Pharma, Inc.
+1.47%
+$101,238.56 
FHTX Foghorn Therapeutics Inc.
+1.45%
+$6,027.78 
PHAT Phathom Pharmaceuticals Inc.
+1.41%
+$8,197.5 
ZYME Zymeworks Inc.
+1.37%
+$46,434.52 
LLY Eli Lilly and Company
+1.26%
+$86,940.06 
ABVX Abivax SA ADR
+1.24%
+$123,788.72 
ABBV AbbVie Inc.
+1.02%
+$62,189.93 
ALKS Alkermes plc
+0.98%
+$25,250 
LRMR Larimar Therapeutics Inc.
+0.91%
+$5,832.3 
CRBP Corbus Pharmaceuticals Holdings, Inc.
+0.84%
+$32,688.81 
RARE Ultragenyx Pharmaceutical Inc.
+0.79%
+$7,907.4 
ENTX Entera Bio Ltd.
+0.75%
+$348.9 
QURE uniQure N.V.
+0.6%
+$7,488 
BIOA BioAge Labs, Inc.
+0.59%
+$7,950 
JNJ Johnson & Johnson
+0.59%
+$78,774.51 
TGTX TG Therapeutics, Inc.
+0.53%
+$58,974.48 
AYTU Aytu BioPharma Inc.
+0.46%
+$3,530.77 
UPB Upstream Bio, Inc.
+0.43%
+$648.27 
BMRN Biomarin Pharmaceutical Inc.
+0.31%
+$27,422.37 
UTHR United Therapeutics Corporation
+0.21%
+$30,716.69 
PASG Passage Bio Inc.
+0.21%
+$195.3 
BCYC Bicycle Therapeutics plc American Depositary Receipt
+0.12%
+$2,382.12 
IMCR Immunocore Holdings plc American Depositary Receipt
+0.11%
+$6,974.12 
UNCY Unicycive Therapeutics Inc.
+0.09%
+$530.41 
VRTX Vertex Pharmaceuticals Incorporated
+0.06%
+$1,113.64 
10806XAJ1
0%
$0 
CNTB Connect Biopharma Holdings Ltd.
0%
$0 
TERN Terns Pharmaceuticals, Inc.
0%
$0 
PTHS Pelthos Therapeutics Inc.
-3.37%
-$22,791.16 
OCGN Ocugen Inc.
-2.26%
-$6,020 
ANNX Annexon, Inc.
-2.24%
-$16,614.5 
RCKT Rocket Pharmaceuticals Inc.
-1.31%
-$1,376.06 
VTGN VistaGen Therapeutics Inc.
-1.3%
-$316.28 
TENX Tenax Therapeutics Inc.
-0.99%
-$27,859.39 
INO Inovio Pharmaceuticals, Inc.
-0.92%
-$5,626.65 
NVO Novo Nordisk A/S Sponsored ADR
-0.62%
-$4,518.87 
CAPR Capricor Therapeutics Inc.
-0.36%
-$5,614.19 
TARS Tarsus Pharmaceuticals Inc.
-0.35%
-$5,058.69 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 355 | Longs Won 156/355 43% | Profit Factor 3.5 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $779,124.87 |
| Average Win $575,790.65 | Best Trade (Jul 19) $5.53M | Sharpe Ratio -17.76 |
| Average Loss -$128,881.59 | Worst Trade (Dec 31) -$5.64M | Z-Score 0.07 (5.2%) |
| Commissions $0 | Avg. Trade Length 5m 1w 5d | Expectancy $180,777.2 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 2,079 | 1,871 | 1,663 | 1,455 | 1,247 | 1,040 | 832 | 624 | 416 | 208 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Zachary Canonico?
The largest contributions to the portfolio's profits come from the following stocks: Terns Pharmaceuticals, Inc - $7.96M, Regeneron Pharmaceuticals, Inc - $3.34M, INDV - $2.99M, Neurocrine Biosciences Inc - $2.32M, and Cogent Biosciences, Inc - $2.3M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Soleno Therapeutics, Inc - $5.32M, Eli Lilly and Company - $830,210.56, VistaGen Therapeutics Inc - $682,458.03, Alnylam Pharmaceuticals Inc - $583,499.34, and Replimune Group Inc - $573,121.38. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Zachary Canonico's portfolio generate?
The portfolio generates substantial dividend income, with a total of $803,812.14 earned over time. The largest contributors to dividend income include Bristol-Myers Squibb Company - $179,800, Johnson & Johnson - $158,430.34, Amgen Inc - $123,998, AbbVie Inc - $123,620.34, and Regeneron Pharmaceuticals, Inc - $67,405.6. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Zachary Canonico's monthly returns?
Zachary Canonico's monthly returns appear quite volatile. The gap between stronger and weaker months is meaningful, which suggests that the strategy can experience noticeable swings over relatively short periods. For users assessing this profile, that usually means returns may be attractive over time, but the path can be uneven and harder to tolerate during weaker periods.
Can Zachary Canonico's strategy be considered aggressive or moderate?
Zachary Canonico's strategy can be described as moderate. It balances growth potential with risk management, showing a willingness to accept some volatility while still maintaining a relatively structured and diversified approach.
Should beginners follow Zachary Canonico's strategy?
Zachary Canonico's strategy is probably not ideal for beginners. The combination of risk, volatility, or portfolio complexity may make it harder to follow and understand without prior experience. Users who are new to investing may find it challenging to replicate or tolerate the performance swings.
